中国癌症杂志 ›› 2013, Vol. 23 ›› Issue (10): 798-803.doi: 10.3969/j.issn.1007-3969.2013.10.004

• 论著 • 上一篇    下一篇

18F-SFB-Annexin B1探测化疗后肿瘤细胞凋亡的实验研究

郑宇佳,王明伟,张建平,徐俊彦,杨忠毅,程竞仪,张勇平,章英剑   

  1. 复旦大学附属肿瘤医院核医学科,复旦大学上海医学院肿瘤学系,上海200032
  • 出版日期:2013-10-25 发布日期:2014-02-19
  • 通信作者: 章英剑 E-mail:yjzhang111@Yahoo.com.cn

Experimental study on tumor response to chemotherapy with 18F-SFB-Annexin B1

ZHENG Yu-jia,WANG Ming-wei,ZHANG Jian-ping,XU Jun-yan,YANG Zhong-yi,CHENG Jing-yi,ZHANG Yong-ping,ZHANG Ying-jian   

  1. Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2013-10-25 Online:2014-02-19
  • Contact: ZHANG Ying-jian E-mail: yjzhang111@Yahoo.com.cn

摘要: 背景与目的:诱导细胞凋亡是肿瘤化疗的机制之一,分子影像能在活体内无创、动态地检测细胞凋亡,有助于药物筛选和疗效分析。本研究旨在探讨N-琥珀酰亚胺-4-氟苯甲酸酯偶联的氟-18-膜联蛋白B1(18F-SFB-AnnexinB1)显像剂早期评价化疗诱导细胞凋亡的可行性。方法:以SFB作为中间体将18F标记到AnnexinB1上。了解18F-SFB-Annexin B1在健康小鼠体内的生物分布特性。建立Walker-256荷瘤小鼠模型,随机分为两组,化疗组腹腔注射环磷酰胺(CTX 200 mg/kg,n=3),对照组注射等体积无菌0.9%的氯化钠溶液(n=3)。24 h后静脉注射18F-SFB-Annexin B1,分别于注射后1、2、3、4 h进行PET/CT显像。比较肿瘤/肌肉放射性摄取率比值(T/M)与原位缺口末端标记(TUNEL)染色法测定凋亡指数(AI)的关系。结果:18F-SFBAnnexinB1放化纯度>95%,生物分布显示肾脏放射性最高,其次为肝、脾和心肌,显像剂在体内清除速率快。化疗组与对照组各时间点T/M比值分别为4.38±0.56、6.75±1.16、6.44±1.12、4.81±0.17和2.35±0.14、2.99±0.55、3.04±0.41、2.33±0.47,差异有统计学意义(F分别为23.790、16.913、14.046、77.517,P均<0.05)。TUNEL染色AI分别为(21.00±0.04)%和(8.58±0.01)%,差异有统计学意义(F=21.539,P<0.05),且T/M值与AI间有很好的相关性(r=0.91,P<0.05)。结论:18F-SFB-AnnexinB1能早期反映化疗诱导的细胞凋亡,有望用于活体细胞凋亡分子显像和早期疗效判断。

关键词: 膜联蛋白B1, 凋亡, 放射性核素显像, 化学疗法, 疗效评价

Abstract:

Background and purpose: One of the main mechanism of chemotherapy is inducing tumor apoptosis. Molecular imaging can allow noninvasively and dynamically monitor tumor apoptosis in vivo, and help to drug screening and therapeutic evaluation. The purpose of this study was to evaluate the feasibility of 18F-SFB-Annexin B1 in detecting apoptosis at an early phase after chemotheraphy. Methods: Annexin B1 was labeled with 18F using SFB as a chelating agent. Tissue distribution of 18F-SFB-Annexin B1 was studied in healthy mice by the dissection method. W256 tumor-bearing rats were injected with 18F-SFB-Annexin B1 intravenously at 24 h after the treatment of cyclophosphamide (CTX 200 mg/kg) or saline. Then imaging was acquired at 1, 2, 3, and 4 h postinjection on a PET/CT, and the tumor-to-muscle ratio of SUVmax (T/M) and the AI from TUNEL testing were compared. Results: 18F-SFBAnnexin B1 had a radiochemical pruity (RCP)>95%. Biodistribution of this probe showed a predominant uptake in the kidney, then was liver, spleen, and myocardium, rapid clearance from blood and urinary was observed. The radios of T/M were 4.38±0.56, 6.75±1.16, 6.44±1.12, 4.81±0.17, respectively at 1, 2, 3, 4 h post injection of the chemotherapy group, much higher than that of the saline group (2.35±0.14, 2.99±0.55, 3.04±0.41, 2.33±0.47, respectively). The differences between the two groups were significant (F=23.790, 16.913, 14.046, 77.517, respectively, all P<0.05). TUNEL staining revealed that chemotherapy treatment significantly increased the percentage of apoptosis cells with an AI of (21.00±0.04)% in the chemotherapy group, higher than that in the saline group (8.58±0.01)%, the difference was significant (F=21.539, P0.05). The radios of T/M were significantly correlated with the values of AI (r=0.91, P0.05). Conclusion: 18F-SFB-Annexin B1 can be used to apoptosis imaging and early therapeutic evaluation in vivo because it can reflect apoptosis at an early stage after chemotheraphy.

Key words: Annexin B1, Apoptosis, Radionuclide imaging, Chemotherapy, Response evaluation